"So far for indications such as heart failure and spinal disc healing the goal posts have shifted to post hoc analysis of surrogate end points and softer targets such "reduced GI bleeding" and "reduced back pain", and the number of patients in the trials required to show statistical significance has increased."
Are you talking about other companies researching heart failure and back pain or are you referring to the Mesoblast trials which have P3 results coming out this quarter?
MSB Trading 2020 - a new dawn, page-8369
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |